Ask AI
Latest Guidelines for Myeloma Management

CE / CME

Myeloma Masterclass: Applying the Latest Guidelines for Evidence-Based, Equitable Care

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Registered Nurses: 1.50 Nursing contact hour

Physician Assistants: maximum of 1.50 hours of AAPA Category 1 CME credits

Pharmacists: 1.50 contact hours (0.15 CEUs)

ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

Released: June 19, 2025

Expiration: December 18, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

How would you rate your level of confidence to identify patients with high-risk smoldering myeloma who may benefit from counseling on systemic treatment options based on current guidelines, risk assessment features, and the latest myeloma diagnostic and staging criteria?

2.

Patient Case 2: A 60-Yr-Old Man With Back Pain Lasting 2-3 Mo



  • 60-yr-old man presents to his PCP with back pain that has been bothering him for the past 2-3 mo

  • X-rays show compression fractures of T11 and L2  skeletal survey shows diffuse lytic lesions concerning for myeloma

  • Blood tests results: hemoglobin 11.6 g/dL, normal platelets and WBC

  • Normal metabolic panel

  • β2M 4.6 mg/dL, LDH normal

  • SPEP: 3.2 g/dL M spike, IgA kappa, FLC: kappa 67 mg/dL, lambda 1.1 mg/dL

  • Marrow shows 40% plasma cells (PC proliferation rate: 1.2%)

  • FISH shows t(4;14), del13q 

Which of the following treatments might you consider for this patient with newly diagnosed multiple myeloma based on the available clinical data and NCCN guidelines?

3.

Patient Case 3: 54-Yr-Old Man Diagnosed With rISS Stage III MM



  • Dan is a 54-yr-old man who was diagnosed with rISS stage III IgA kappa MM in 2023

  • FISH revealed 1q+ and t(4;14)

  • He received Dara-VRd x 4 cycles followed by ASCT (2024) followed by lenalidomide/daratumumab maintenance therapy

  • Achieved MRD-negative CR for 18 mo

  • He has developed a symptomatic relapse with new FDG-avid bone lesions and recurrence of his original IgA kappa paraprotein  

Which of the following would be the optimal next therapy for a patient with relapse after Dara-VRd and ASCT?